Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | THPO | P40225 | 3/20 | 0.70 |
| ▸ | FPR2 | P25090 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.69 |
| ▸ | SCN1A | P35498 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508099 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL15760997 | 0.84 | CYP3A4 (0.78) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL29695235 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL166960 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL9927435 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL12648358 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL317323 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL29653788 | 0.83 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9895302 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL897995 | 0.82 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226281-A1 | COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY | SIRENAS LLC (US) | 2022-07-21 | — | — | US | claimed |
| US-20220062345-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE C ACTIVATOR-TREATED STEM CELLS OR CULTURE THEREOF FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES | CORESTEM CO.,LTD. (JP) | 2022-03-03 | — | — | US | claimed |
| EP-3878458-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PROTEIN KINASE C ACTIVATOR-TREATED STEM CELLS OR CULTURE THEREOF FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES | Corestem Co., Ltd. (KR) | 2021-09-15 | — | — | EP | claimed |
| US-10010584-B2 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY (US) | 2018-07-03 | — | — | US | claimed |
| US-20160257930-A1 | NEURONAL STEM CELL DIFFERENTIATION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-09-08 | — | — | US | claimed |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | BLANCHETTE ROCKEFELLER NEUROSCIENCE INSTITUTE (US) | 2013-06-27 | — | — | US | claimed |
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2013-06-27 | — | — | US | claimed |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | WEST VIRGINIA UNIVERSITY | 2011-11-24 | — | — | US | claimed |
| US-20110245307-A1 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2011-10-06 | — | — | US | claimed |
| US-7803400-B2 | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-09-28 | — | — | US | claimed |
| US-20090030055-A1 | PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE | 2009-01-29 | — | — | US | claimed |
| US-12516295-B2 | Generation of pancreatic progenitor cells and beta cells from human pluripotent stem cells | THE PENN STATE RESEARCH FOUNDATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3967299-B1 | PKC ACTIVATORS AND COMBINATIONS THEREOF FOR TREATING ALZHEIMER DISEASE | COGNITIVE RES ENTERPRISES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250064776-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | Synaptogenix, Inc. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240390324-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | Synaptogenix, Inc. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20080003181-A1 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY | 2008-01-03 | — | — | US | disclosed |
| US-20080003181-A1 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY | 2008-01-03 | — | — | US | disclosed |
| US-20080003181-A1 | Treatment of depressive disorders | WEST VIRGINIA UNIVERSITY | 2008-01-03 | — | — | US | disclosed |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | ALKON DANIEL L | 2008-01-03 | — | — | US | disclosed |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | ALKON DANIEL L | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226281-A1 | COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY | NFATC1, PRKCQ, PRKCZ | CYP3A4 4837/4885CYP1A2 4823/4885CYP2C19 4864/4885 |
| US-20090030055-A1 | PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds | GSAP, BACE1, PRKCH | CYP3A4 3847/4885CYP1A2 4402/4885CYP2C19 4744/4885 |
| US-20130165453-A1 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY | BDNF, NGF, NTRK2 | CYP3A4 4450/4885CYP1A2 4515/4885CYP2C19 4658/4885 |
| US-20110288022-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | CYP3A4 3997/4885CYP1A2 2466/4885CYP2C19 1961/4885 |
| US-20110245307-A1 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement | BACE1, PRKCH, GSAP | CYP3A4 4094/4885CYP1A2 4519/4885CYP2C19 4688/4885 |
| US-20240390324-A1 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | BDNF, HGF, NGF | CYP3A4 4882/4885CYP1A2 4875/4885CYP2C19 4883/4885 |
| US-20080004332-A1 | Methods for alzheimer's disease treatment and cognitive enhancement | BACE1, PRKCH, GSAP | CYP3A4 4094/4885CYP1A2 4519/4885CYP2C19 4688/4885 |
| US-20130165375-A1 | TREATMENT OF DEPRESSIVE DISORDERS | FGF1, FGFR1, FGFR3 | CYP3A4 3972/4885CYP1A2 2458/4885CYP2C19 1941/4885 |
| US-20250064776-A1 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PKC ACTIVATORS | PARK7, PMAIP1, SMN1; SMN2 | CYP3A4 4598/4885CYP1A2 4622/4885CYP2C19 4737/4885 |
| US-20080003181-A1 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | CYP3A4 3997/4885CYP1A2 2466/4885CYP2C19 1961/4885 |
| US-10010584-B2 | Treatment of depressive disorders | FGF1, FGFR1, FGFR3 | CYP3A4 3972/4885CYP1A2 2458/4885CYP2C19 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.